Online inquiry

IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10897MR)

This product GTTS-WQ10897MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL1A gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC), Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552
UniProt ID P01583
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10897MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7223MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ15970MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ4290MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ9741MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ9694MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ1135MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ13177MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ11602MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW